Fibrates are PPARα agonists used to treat dyslipidemia, thiazolidinediones (TZDs) are PPARγ agonists used to treat type 2 diabetes, and the glitazars are dual PPARα and PPARγ agonists used to treat dyslipidemia and type 2 diabetes comorbidities. Here, PPARA is linked to type 2 diabetes mellitus.